Castrejón-Pérez Ana Daniela, Welsh Esperanza C, Miranda Ivett, Ocampo-Candiani Jorge, Welsh Oliverio
Department of Dermatology, Universidad Autonoma de Nuevo Leon, School of Medicine, University Hospital Dr. Jose Eleuterio Gonzalez - Monterrey, Mexico.
An Bras Dermatol. 2017 May-Jun;92(3):304-311. doi: 10.1590/abd1806-4841.20176614.
Cutaneous mucormycosis is an emerging fungal infection caused by opportunistic fungi of the phylum Glomeromycota. It is frequent in poorly controlled diabetic patients and individuals with immunosuppression. It is usually acquired by direct inoculation through trauma. The clinical presentation is nonspecific, but an indurated plaque that rapidly evolves to necrosis is a common finding. Diagnosis should be confirmed by demonstration of the etiological agent and new molecular diagnostic tools have recently been described. It is an invasive life-threatening disease and in order to improve survival, a prompt diagnosis and multidisciplinary management should be provided. The treatment of choice is amphotericin B, but new azoles, such as posaconazole and isavuconazole, must be considered.
皮肤毛霉病是一种由球囊菌门的机会性真菌引起的新发真菌感染。在血糖控制不佳的糖尿病患者和免疫抑制个体中较为常见。通常通过创伤直接接种感染。临床表现不具特异性，但迅速发展为坏死的硬结斑块是常见表现。诊断应通过病原体的鉴定来确认，最近已有新的分子诊断工具被描述。这是一种具有侵袭性且危及生命的疾病，为提高生存率，应进行快速诊断和多学科管理。首选治疗药物是两性霉素B，但也必须考虑新型唑类药物，如泊沙康唑和艾沙康唑。
